Multiple Myeloma | Specialty

Gene Expression Profiling in Multiple Myeloma

January 12th 2015

Introduction: Redefining Symptomatic Multiple Myeloma

January 12th 2015

Dr. Morgan on the Future of Myeloma Treatment

January 2nd 2015

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

Dr. Ghobrial on Antibodies for Multiple Myeloma Treatment

December 29th 2014

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.

Two Experts Discuss JAK Inhibition in Polycythemia Vera

December 11th 2014

2014 ASH Annual Meeting

December 11th 2014

RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

December 11th 2014

Dr. Raje Discusses Anti-CD38 Antibodies in Myeloma

December 8th 2014

Noopur Raje, MD, from the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

Elotuzumab Produces Impressive Response Rate in Relapsed/Refractory Multiple Myeloma

December 8th 2014

Treatment with elotuzumab in combination with lenalidomide and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma.

Anti-CD38 Antibodies Highly Effective in Multiple Myeloma

December 7th 2014

Two studies spotlighted at the 2014 ASH Annual Meeting characterized the efficacy of treatment with anti-CD38 monoclonal antibodies in the frontline setting and for patients with refractory disease.

Carfilzomib Combination Significantly Increases PFS in Relapsed Multiple Myeloma

December 7th 2014

Treatment with carfilzomib in combination with lenalidomide and dexamethasone increased PFS by 8.7 months in patients with relapsed multiple myeloma when compared with lenalidomide and dexamethasone alone.

Dr. Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial

December 6th 2014

A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Analyzing CTCs Using Next-Generation Sequencing

December 5th 2014

Next-Generation of CTC Technology

December 5th 2014

Clinical Utility of Circulating Tumor Cells

December 5th 2014

Latest News & Insight: December 5, 2014

December 5th 2014

Anderson Provides Insight Into Novel Agents in Multiple Myeloma

November 26th 2014

The treatment of patients with multiple myeloma is poised to undergo a dramatic transformation, as novel monoclonal antibodies and combination strategies race toward approval.

FDA Extends Panobinostat Review Period for Multiple Myeloma

November 25th 2014

The FDA has extended the review period for panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone for patients with previously treated multiple myeloma by 3 months, placing a new decision date in early 2015.

ODAC Votes Against Panobinostat in Multiple Myeloma

November 6th 2014

In what was described as a very difficult decision, ODAC voted 5-2 against the accelerated approval of the HDAC inhibitor panobinostat in combination with bortezomib and dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.

Three Specialists Offer Outlook on Employing Pomalidomide in Multiple Myeloma

November 4th 2014

As therapy options for patients with relapsed or refractory multiple myeloma have expanded in recent years, so have clinical considerations about how best to incorporate new agents into the treatment paradigm.